Consciousness and Cognition
June 19, 2024
Dmitri Filimonov, Sampo Tanskanen, Antti Revonsuo et al.
The level-of-processing (LoP) hypothesis postulates that transition from unaware to aware visual stimuli is either graded or dichotomous depending on the depth of stimulus processing. Humans can be progressively aware of the low-level features, such as colors or shapes, while the high-level features, such as semantic category, enter consciousness in an all-or none fashion. Unlike in vision,...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
June 17, 2024
Hugo R Arias, L. Micheli, Deborah Rudin et al.
14 citations
The aim of this study was to determine the anti-hypersensitivity activity of novel non-hallucinogenic compounds derived from iboga alkaloids (i.e., ibogalogs), including tabernanthalog (TBG), ibogainalog (IBG), and ibogaminalog (DM506), using mouse models of neuropathic (Chronic Constriction Injury; CCI) and visceral pain (dextrane sulfate sodium; DSS). Ibogalogs decreased mechanical...
Current Medical Research and Opinion
June 17, 2024
Francisco J Appiani, Stanley N. Caroff
5 citations
There is an increasing demand for effective treatments for depression, particularly for individuals grappling with treatment-resistant depression. Over recent years, a surge of interest has focused on exploring the safety and efficacy of psilocybin as a potential treatment for depression. However, preliminary findings from phase 2 studies have been inconclusive, prompting critical examination...
Journal of Clinical Investigation
June 17, 2024
Alejandro Torrado Pacheco, Bita Moghaddam
3 citations
Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiatric disorders. All clinical data collected so far with regard to psilocybin or MDMA, which have reported positive outcomes for treating depression, anxiety, posttraumatic stress disorder, and drug or alcohol use disorders, have involved...
Neuroscience of Consciousness
June 15, 2024
Paolo Cardone, Naji Alnagger, Jitka Annen et al.
16 citations
Modern medicine has been shaken by the surge of psychedelic science that proposes a new approach to mitigate mental disorders, such as depression and post-traumatic stress disorder. Clinical trials to investigate whether psychedelic substances can treat psychiatric conditions are now underway, yet less discussion gravitates around their use in neurological disorders due to brain injury. One...
Journal of Psychopharmacology
June 14, 2024
Vince Polito, Paul Liknaitzky
16 citations
Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by expectations or placebo effects. In this rapid review, we aimed to evaluate the strength of evidence for a placebo explanation of the reported effects of microdosing. We conducted a PubMed search for all studies investigating psychedelic microdosing...
International Journal of Molecular Sciences
June 13, 2024
Teodora Vidonja Uzelac, Nikola Tatalović, Milica Mijović et al.
6 citations
Ibogaine is an organic indole alkaloid that is used in alternative medicine to combat addiction. Numerous cases of life-threatening complications and sudden deaths associated with ibogaine use have been reported, and it has been hypothesized that the adverse effects are related to ibogaine's tendency to induce cardiac arrhythmias. Considering that the bioavailability of ibogaine and its primary...
Frontiers in Psychiatry
June 10, 2024
Leehe Peled-Avron, Jacob S. Aday, Amilia Lydia Kalafateli et al.
2 citations
Editorial on the Research Topic Down the rabbit hole -the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions Psychedelic substances have demonstrated promising therapeutic effects across a wide range of mental health conditions including depression (1-13) anxiety disorders including generalized anxiety (14-16) and social...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
June 8, 2024
Kaylene K A Scheil, Carla L Sánchez-Lafuente, Brady S Reive et al.
5 citations
There is an urgent need for novel antidepressants, given that approximately 30% of those diagnosed with depression do not respond adequately to first-line treatment. Additionally, monoaminergic-based antidepressants have a substantial therapeutic time-lag, often taking months to reach full therapeutic effect. Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist is the only current...
June 7, 2024
Mika Turkia
preprint
Ketamine is a well-known and widely available general anesthetic from the 1960s that, in sub-anesthetic doses, has been adopted in a limited manner for the treatment of acute suicidality and treatment-resistant depression. Its short onset time and short duration of action make it feasible for use at outpatient clinics. In the US, it has a long history of off-label use and was officially...